State of China Life Science – 2019

2018 another record year! What does 2019 hold?

China Showcase - January 6, 2019 Greg B. Scott, Founder

> CHINABIO[®] GROUP Consulting | Capital | Conferences

General Distribution

© Copyright 2019 ChinaBio LLC

VC Fund Raising	VC/PE Investment	M&A	IPO	Partnering

Topics

- Overview
- Investment Activity
 - VC/PE Funds Raised
 - VC/PE Investment
 - M&A Activity
 - IPOs
- Partnering Activity

IPO

2018 Investment Activity: New records set across the board

Area	2018	2008	10 Year Growth	2017	YoY	Trend
Funds Raised	\$42.8B	\$1.2B*	36X	\$39.8B	7.5%	$\widehat{1}$
VC Investment	\$17.4B	\$327M	53X	\$12.7B	36%	AMA ANA
M&A	\$34.2B	\$1.8B	19X	\$22.3B	53%	AW A
IPO	\$6.9B	\$168M	36X	\$4.9B	41%	A MA
Partnering	\$13.8B	\$726M	19X	\$8.3B	66%	AMA ANA

Overall factors driving China life science investment

"It's the golden era of healthcare in China"

- Robust Government Support
 - \$100B+ / yr in funding, improving healthcare policies
- Significant VC/PE Funding
 - China on par with and about to exceed US investing in life science
- Sweeping Regulatory Changes
 - Significant move toward global standardization; ICH membership
- Strong Talent Base
 - Over 2 million returnees in last 6 years, ~250,000 in life science
- Major Socio-economic Trends
 - 6.5% in GDP growth; 300M+ middle class with \$\$
 - aging population (31% by 2050); chronic disease up 20-30%/yr
 - #2 pharma market, #1 by 2020 with >\$1T in HC spending

Investment Activity


ChinaBio[®] has helped raise over \$500M in funding for western and China-based life science companies

IPO


VC/PE funds raised grew 7.5% in 2018 Fewer but larger funds; H2 slowed slightly

VC/PE Funds Raised Targeting China Healthcare

Record \$764M average fund size




Investment flowing into China life science jumped 36% with record average deal size, but H2 slowed



VC/PE Investment in China Healthcare

Drug companies received largest VC investment followed by iHealth companies




M&A

IPO

VC Investment: Deals of Note 2018 (1)

Company	Туре	Investors	Month	Amount (\$)	
Moderna Therapeutics	Drug	Abu Dhabi Investment Bureau, Sequoia, BB Biotech AG, Arrowmark Partners	Feb.	\$500M	
Grail	Diagnostic	Ally Bridge, Hillhouse, 6 Dimensions, Blue Pool, ICBC International, Decheng	Мау	\$300M	
CStone Pharmaceuticals	Drug	GIC Private Limited, Sequoia, ARCH, Hillhouse, Yunfeng Capital, CITIC PE	Мау	\$260M	
Brii Biosciences	Drug	ARCH, 6 Dimensions, Yunfeng Capital, Sequoia Capital, Blue Pool Capital, Boyu Capital	Мау	\$260M	
Ping An Healthcare	iHealth	IDG Venture, SBI Investment, SoftBank	Feb.	\$1.2B	



Source: ChinaBio[®] Consulting

M&A

IPO

VC Investment: Deals of Note 2018 (2)

Company	Туре	Investors	Month	Amount (\$)	
Innovent	Drug	Capital Group, Temasek, Hillhouse, Legend Capital, Lilly Asia Ventures, Taikang Insurance, Cormorant, Rock Springs, Ally Bridge	Apr.	\$150M	
China Diagnostic Medical	Diagnostic	Legend Capital	Aug.	\$292M	
I-Mab Biopharma	Drug	Hony Capital, Hillhouse, HOPU Investments, CDH	June	\$220M	
LinkDoc	iHealth	China Investment Corporation	July	\$151M	
Tasly Biopharma	Drug	Ally Bridge	July	\$150M	


Source: ChinaBio[®] Consulting

© Copyright 2019 ChinaBio LLC

Cross-border Deals

M&A: 7th record year, up over 50% from 2017

M&A Activity in China Healthcare Record \$209M average deal size




Source: ChinaBio[®] Consulting

CHINABIO[®]

VC/PE Investment

M&A



M&A Activity 2013-2018

IPO

Source: ChinaBio® Consulting

CHINABIO[®]

VC Fund Raising

Partnering

15%

10%

8%

iHealth

IPO

M&A: Deals of Note 2018

Outbound cross-border acquisitions remain active

Acquirer	Target	Туре	Date	Amount (\$)	
Alibaba	iKang Healthcare	Service	Mar.	\$1.4B	
Alibaba Health Information Technology	JK Medical Products Limited	iHealth	Мау.	\$1.4B	
China Grand Pharmaceutical	Sirtex Medical	Device	Jun.	\$1.4B	
China Resources Pharma	Jiangzhong Group	Drug	Мау.	\$613M	
China consortium including Jianyin Investement (JIC) & Tamar Alliance	Natures Care Manufacture Pty	Drug	Apr.	\$600M	
Harbin Pharmaceutical Group	GNC Holdings	Drug	Feb.	\$300M	
Shanghai Pharma	Techpool Bio-Pharma	Drug	Мау.	\$280M	
Shanghai RAAS	Grifols Diagnostic Solutions Inc	Drug	Nov.	\$5B	
Source: ChinaBio [®] Consulting			A SUD	Cross-border D	Deals

 $CHINABIO^{\circ}$



IPOs in China Healthcare

M&A

IPO: Deals of Note 2018


Company Name	Exchange	Stock Ticker	Capital Raised (USD)	Company Type	Month
ARMO BioSciences	NSDQ	ARMO	\$123 M	Drug	Jan.
Ping An Healthcare (Good Doctor)	HKSE	01833	\$1.0B	iHealth	Мау
BeiGene	HKSE	06160	\$870M	Drug	Aug.
Ascletis Pharma	HKSE	01672	\$380M	Drug	Aug.
WuXi AppTec	SSE	603259	\$350M	Service	Мау
Mindray	GEM	300760	\$870M	Medical Devices	Oct.
Innovent Biologics	HKSE	01801	\$400M	Drug	Oct.
WuXi АррТес	HKSE	02359	\$1.0B	Service	Dec.

Partnering Activity

ChinaBio[®] has identified over 1000 partnering, licensing and acquisition candidates for western life science companies

New record set for partnering at \$13.8B, up 66% Major activity in H2 – no slowdown in cross-border

VC/PE Investment



Partnering Deals in China Healthcare

M&A

IPO

Source: ChinaBio® Consulting

Partnering and JV deals

Partnering


CHINABIO[®]

VC Fund Raising

Number of pharma partnering deals jumps 63% and cross-border partnering increases 70%

Cross-border Pharma Partnering

Represents >75% of all pharma partnering



Source: ChinaBio[®] Consulting


Partnering and JV deals, 2018

Partnering by Clinical Stage: Preclinical #1 (35%), followed by marketed assets (24%)

Cross-border Pharma Partnering by Clinical Stage

Preclinical down somewhat from 24% and marketed assets up from 15%

Clinical Stage




Source: ChinaBio[®] Consulting

Partnering and JV deals, 2018

Oncology still dominating partnering activity at 31% followed by neurology, the fastest growing indication

Pharma Partnering by Indication – 2018 (# of deals)



Partnering: Deals of Note 2018 (1)

Company A	Company B	Туре	Month	Brief Description	
BeiGene	Zymeworks	Drug	Nov.	BeiGene acquires Asian rights to cancer drugs in deal worth up to \$1.3 billion	
Luye Pharma	AstraZeneca	Drug	Мау	Luye acquired rights to AZ's antipsychotic drug Seroquel in 51 countries including China, UK, Brazil, Australia, etc.	
WuXi Biologics	Oxford Bio Therapeutics	Service	Dec.	WuXi Biologics out-licensed a double antibody to OBT for \$450 million	
CStone	Agios	Drug	June	CStone licensed agreement for the development and commercialization of ivosidenib	
CStone	Blueprint Medicines	Drug	June	CStone in-licenced three drugs from US-based Blueprint Medicines	
Antegene	Karyopharm Therapeutics	Drug	Мау	Antegene receives Asian rights to four oncology assets	

M&A

Partnering: Deals of Note 2018 (2)

Company A	Company B	Туре	Month	Brief Description	
Oncologie	Mologene AG	Drug	Nov.	Mologene signed a global assignment of all intellectual property and other rights agreement with Oncologie	
Xyonomic	Boehringer Ingelheim	Drug	Dec.	Xynomic acquired cancer candidate in \$800 million deal	
Innovent	Incyte	Drug	Dec.	Innovent formed a \$390M collaboration for China rights to three clinical-stage drug candidates developed by Incyte	
Hengrui Pharma	TG Therapeutics	Drug	Jan.	TG Therapeutic in-licenced 3 BTK inhibitors from Hengrui	
Fosun	Revance	Drug	Dec	Fosun Pharma acquired rights to Botox- type drug for \$260M	

ChinaBio® Introduction

Your trusted partner in China life science™



ChinaBio[®] is focused solely on helping life science companies and investors in the US, EU and APAC achieve success in China

ChinaBio[®] Partnering Forum: May 8-9, 2019, Shanghai Largest global partnering conference in China...

WHAT TO EXPECT IN 2019

Company

1,200+ 80+

Attendees



25+

presentations

RETURING TO SHANGHAI

Zhangjiang Hi-Tech Park

First & largest park in China
Roche, BI, Amgen, AZ, GSK,

2,500+

One-to-one

meetings

Over 1,500 life science cos. Novartis, Pfizer, Zai Lab

ChinaBio2019.com Co-produced by

Co-produced by CHINABIO. EEDGROUP

CHINABIO PARTNERING FORUM 合作论坛 2019

MAY 8-9, 2019 // SHANGHAI, CHINA

Thank you! 谢谢你!

Contact information:

Greg Scott, Founder ChinaBio® Group Shanghai | San Diego | Silicon Valley | Basel China Tel: +86 21 5137 0751 US Tel: +1 858 859 1960 Email: greg.scott@chinabio.com Web: www.ChinaBio.com